Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suplatast tosilate for cough in idiopathic pulmonary fibrosis
NCT05983471Phase 2Active, not recruiting
- Sponsor
- Melius Pharma AB
- Start
- Apr 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of suplatast tosilate in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Melius Pharma AB. Primary endpoint: Wake time cough frequency during 24 hours at 14 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
suplatast tosilate
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05983471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983471.